Table 1.

Characteristics of Viral Population Dynamics and Treatment Response in Patients With Treatment Failure

ID	Clinical Outcome	Pairwise Distance (Sanger)*	Pairwise Distance (NGS)†	New Dominance‡	New Variants§	Final Conclusion
P38	Null response	0.19	0.08	-	1	Persistent infection (New variant detected)
P63	Null response	0.03	0	-	0	Persistent infection
P67	Null response	0.04	0.04	-	0	Persistent infection
P81	Null response	0.48	0.06	13%	1	Persistent infection (New dominance and new variant detected)
P112	Null response	0.17	0.01	-	0	Persistent infection
P118	Null response	0.47	0.01	3%	0	Persistent infection (New dominance)
P21	Partial response	0.27	0	NA	1	Persistent infection (New dominance and new variant detected)
P31	Partial response	0.08	0.08	-	0	Persistent infection
P105	Partial response	0.46	0	-	1	Persistent infection (New variant detected)
P75	Relapse	0	0	-	1	Persistent infection (New variant detected)
P76	Relapse	0.24	0.05	3.2%	0	Persistent infection (New dominance)
P101	Relapse	0	0	-	0	Persistent infection
P57	Relapse	0.33	0.03	9%	0	Persistent infection (New dominance)
P131	Relapse	0.27	0.05	-	2	Persistent infection (New variant detected)
P141	Relapse	0.24	0.01	3.9%	0	Persistent infection (New dominance)

^*Outcome is determined by comparing consensus sequence of pre- and posttreatment samples using Sanger sequencing.

^†Pairwise distance is the pairwise distance between the similar variants in paired samples where a new dominance of pre-exisiting minority strain was noticed.

^‡New dominance is the frequency of the new dominant variant of the posttreatment sample detected in the pretreatment sample.

^§Number of new variants detected in posttreatment sample.